Standout Papers
Citation Impact
Citing Papers
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Role of viruses in etiology and pathogenesis of multiple sclerosis
2001
The Brazilian health system: history, advances, and challenges
2011 Standout
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections
1996
EGFR Antagonists in Cancer Treatment
2008 Standout
Expression profiling identifies responder and non‐responder phenotypes to interferon‐β in multiple sclerosis
2003
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
2008
Pediatric multiple sclerosis
2009
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
2005 Standout
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
2006
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
Sjögren's syndrome
2005 Standout
Rheumatoid arthritis
2016 Standout
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
2009 StandoutNobel
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 Standout
The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases
2002 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
2002
Guillain-Barré syndrome
2016 Standout
Vitamin D and Multiple Sclerosis
1997
US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis
2005
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2003
What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update
2006
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
1997
Pediatric Multiple Sclerosis
2011
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
2013
Improving Safety with Information Technology
2003 Standout
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
2013
Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus
2009
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Multiple sclerosis
2008 Standout
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
2008
Lack of evidence for use of glatiramer acetate in multiple sclerosis
2004
Detecting Adverse Events Using Information Technology
2003
The contributions of myelin and axonal caliber to transverse relaxation time in shiverer and neurofilament-deficient mouse models
2010
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis
2017
The origin and application of experimental autoimmune encephalomyelitis
2007
Systemic Lupus Erythematosus
2011 Standout
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
2007
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
Pure optic-spinal form of multiple sclerosis in Japan
2002
A review of MRI findings in schizophrenia
2001 Standout
Axonal Transection in the Lesions of Multiple Sclerosis
1998 Standout
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
2009
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
1998 Standout
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
2010
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
2012 Standout
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
2006
Blood-Brain Barrier Breakdown in the Aging Human Hippocampus
2015 Standout
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
2006
Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor
2003
Multiple Sclerosis
2000 Standout
New Multiple Sclerosis Phenotypic Classification
2014 Standout
In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis
2003
Intrathecal activation of the complement system and disability in multiple sclerosis
1998
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
2008
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Polymyositis and dermatomyositis
2003 Standout
Obstructive sleep apnoea and its cardiovascular consequences
2008 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Matrix metalloproteinases MMP‐9 and MMP‐7 are expressed in experimental autoimmune neuritis and the guillain‐barré syndrome
1998
Expression of specific matrix metalloproteinases in inflammatory myopathies
2001
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
2004 Standout
Head and Neck Cancer
2001 Standout
The dawning era of polymer therapeutics
2003 Standout
Trends in peptide drug discovery
2021
Multiple sclerosis
2002 Standout
Adherence to Medication
2005 Standout
Recent progress in the diagnosis and treatment of multiple sclerosis
1999
Sulfatase-activated fluorophores for rapid discrimination of mycobacterial species and strains
2013 StandoutNobel
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis
2003
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
2000
Adverse drug events in hospitals: a systematic review
2009
Zymographic Techniques for the Analysis of Matrix Metalloproteinases and their Inhibitors
2005
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
Assessing disability progression with the Multiple Sclerosis Functional Composite
2009
Costs of serious adverse events in a community teaching hospital, in Mexico
2015
Multiple Sclerosis
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
2008
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
MRI in the diagnosis of pediatric multiple sclerosis
2008
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
2009
Multiple sclerosis
2004
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Rapid metabolic evolution in human prefrontal cortex
2011 StandoutNobel
Devic’s neuromyelitis optica: a critical review
2008
Dynamic mapping of human cortical development during childhood through early adulthood
2004 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS
2007
The Measurement of Observer Agreement for Categorical Data
1977 Standout
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
2002
Works of Corey C. Ford being referenced
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
2000
Frontal lobe of children with schizophrenia spectrum disorders: A proton magnetic resonance spectroscopic study
1998
Magnetic resonance imaging of experimental demyelinating lesions
1990
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
2007
Brain abnormalities in schizophrenia-spectrum children: implications for a neurodevelopmental perspective
1997
Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis
1996
Quantification of blood-to-brain transfer rate in multiple sclerosis
2012
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
2015
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica
2001
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
2000
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite
2003
Practical approach to determining costs and frequency of adverse drug events in a health care network
2001
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
2006
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
1995 Standout
The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.
2002
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
1998